Skip to search formSkip to main contentSkip to account menu

0.67 ML anakinra 149 MG/ML Prefilled Syringe [Kineret]

Known as: Kineret 100 MG in 0.67 ML Prefilled Syringe, Kineret 100 MG per 0.67 ML Prefilled Syringe, anakinra 100 mg in 0.67 mL SUBCUTANEOUS INJECTION, SOLUTION [Kineret] 
National Institutes of Health

Related topics

Related topics

9 relations
Citric Acid, AnhydrousEdetic Acid, Disodium SaltKineretPolysorbate 80

Broader (1)

anakinra Prefilled Syringe [Kineret]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice
Duchenne muscular dystrophy (DMD) is an X-linked muscle disease caused by mutations in the dystrophin gene. The pathology of DMD… 
2015
2015
Induction de tolérance à l’anakinra (Kineret ® ) pour une maladie de Still dans le cadre d’une réaction d’hypersensibilité retardée
2015
2015
Hypersensibilité retardée allergique à l’anakinra (Kineret®)
2014
2014
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
CAPS is a rare monogenic autoinflammatory syndrome consisting of a spectrum of three conditions: Familial cold autoinflammatory… 
2013
2013
OP0061 Kineret® (Anakinra) Controls Disease Symptoms in Patients with Severe Cryopyrin-Associated Periodic Syndromes (CAPS): Up to 5-Year Follow-Up Data
Background In severe forms of the rare monogenic autoinflammatory syndrome CAPS (NOMID, also denoted CINCA), persistent systemic… 
2013
2013
SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)
Background Interleukin-1 (IL-1) is a potent mediator of of inflammation. Kineret is a recombinant, non-glycosylated form of the… 
2012
2012
Kineret® (anakinra) for injection, for subcutaneous use
  • 2012
  • Corpus ID: 140060644
----------------------DOSAGE AND ADMINISTRATION----------------------Rheumatoid Arthritis (RA) • The recommended dose of Kineret… 
2007
2007
Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra).
Sirs, The treatment of patients with severe systemic idiopathic juvenile arthritis (sJIA) is likely to improve thanks to the… 
2004
2004
Em busca de uma causa à parte da Ortodontia: hereditariedade e reabsorção apical em pacientes tratados ortodonticamente. Uma análise crítica do trabalho de Harris, Kineret e Tolley
2003
2003
Der Interleukin-1-Rezeptorantagonist Anakinra (Kineret®) in der Behandlung mit rheumatoider Arthritis
Zusammenfassung. Die neuen Therapiestrategien bei der rheumatoiden Arthritis zielen insbesondere auf die selektive Hemmung… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)